What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
John C. Byrd spends much of his time researching Chronic lymphocytic leukemia, Internal medicine, Immunology, Leukemia and Cancer research.
Ibrutinib is the focus of his Chronic lymphocytic leukemia research.
His studies deal with areas such as Venetoclax, breakpoint cluster region, Neutropenia and Bruton's tyrosine kinase as well as Ibrutinib.
His studies deal with areas such as Gastroenterology, Surgery and Oncology as well as Internal medicine.
His Leukemia research is multidisciplinary, incorporating perspectives in Cancer, Chemotherapy, Monoclonal, Myeloid and Myeloid leukemia.
The Cancer research study combines topics in areas such as DNA methylation, Apoptosis, Molecular biology, Signal transduction and Kinase.
His most cited work include:
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling (8095 citations)
- Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (1802 citations)
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia (1539 citations)
What are the main themes of his work throughout his whole career to date?
John C. Byrd focuses on Chronic lymphocytic leukemia, Internal medicine, Cancer research, Immunology and Oncology.
His Chronic lymphocytic leukemia study is focused on Leukemia in general.
In his work, Decitabine is strongly intertwined with Myeloid leukemia, which is a subfield of Leukemia.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery.
His Cancer research research includes themes of Apoptosis, B cell, Cytotoxicity, Kinase and In vivo.
John C. Byrd interconnects Clinical trial, Chemotherapy, Phases of clinical research and Chemoimmunotherapy in the investigation of issues within Oncology.
He most often published in these fields:
- Chronic lymphocytic leukemia (44.13%)
- Internal medicine (41.68%)
- Cancer research (28.94%)
What were the highlights of his more recent work (between 2017-2021)?
- Internal medicine (41.68%)
- Chronic lymphocytic leukemia (44.13%)
- Oncology (23.97%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Chronic lymphocytic leukemia, Oncology, Cancer research and Ibrutinib.
His work on Leukemia, Rituximab, Cancer and Venetoclax as part of general Internal medicine study is frequently connected to In patient, therefore bridging the gap between diverse disciplines of science and establishing a new relationship between them.
His Chronic lymphocytic leukemia research incorporates themes from Relapsed refractory, B cell and Phases of clinical research.
His Oncology research is multidisciplinary, incorporating elements of Clinical trial, Refractory, Chemotherapy and NPM1.
John C. Byrd combines subjects such as Cell culture, Bruton's tyrosine kinase, In vivo and Cytotoxicity with his study of Cancer research.
His Ibrutinib study also includes
- Adverse effect that intertwine with fields like Progressive disease,
- Discontinuation, which have a strong connection to Gastroenterology and Neutropenia.
Between 2017 and 2021, his most popular works were:
- iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (392 citations)
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL (289 citations)
- Single-Agent Ibrutinib in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia: A 5-Year Experience (201 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Gene
His primary scientific interests are in Internal medicine, Chronic lymphocytic leukemia, Ibrutinib, Leukemia and Oncology.
As part of one scientific family, John C. Byrd deals mainly with the area of Internal medicine, narrowing it down to issues related to the Gastroenterology, and often Progressive disease.
His studies in Chronic lymphocytic leukemia integrate themes in fields like Cancer research, Neutropenia and Bruton's tyrosine kinase.
His study on Ibrutinib also encompasses disciplines like
- Ofatumumab which connect with Fludarabine,
- Venetoclax together with Phases of clinical research, Obinutuzumab and Minimal residual disease,
- IGHV@ and related Chemotherapy.
His research in Leukemia intersects with topics in Cancer, Clinical trial, Survival rate, Hematology and Myeloid leukemia.
His Oncology research includes elements of Refractory Chronic Lymphocytic Leukemia and Monoclonal.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
